Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Follicular Lymphoma

Therapeutic area intelligence for Follicular Lymphoma with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
7
Catalysts
0
Companies
0

Companies

No related entities indexed yet.

Assets

epcoritamab →
Obinutuzumab →
Rituximab →
Tazemetostat →

Recent signals(7)

ClinicalAugust 18, 2026

Phase I/II Trial of Radiation Therapy and Rituximab for Follicular Lymphoma

A randomized phase I/II trial is underway to evaluate the efficacy of combining radiation therapy with rituximab in patients with stage I-II grade 1 or grade 2 follicular lymphoma, sponsored by M.D. Anderson Cancer Center and NCI.

ClinicalJuly 27, 2026

Phase I Trial of Rituximab, Lenalidomide, and Ibrutinib in Follicular Lymphoma

A phase I trial is investigating the combination of rituximab, lenalidomide, and ibrutinib in patients with untreated stage II-IV follicular lymphoma.

ClinicalJuly 26, 2026

Study on Clonal Evolution in Follicular Lymphoma by NCI

The National Cancer Institute is conducting a study to collect serial samples from untreated adults with follicular lymphoma to understand disease progression and treatment responses.

ClinicalJuly 14, 2026

Phase II Trial of Obinutuzumab Combinations in Relapsed/Refractory Follicular Lymphoma

A phase II trial is evaluating the efficacy of obinutuzumab with or without umbralisib, lenalidomide, or chemotherapy in patients with relapsed or refractory grade I-IIIa follicular lymphoma.

ClinicalJuly 10, 2026

Epcoritamab + Lenalidomide and Rituximab Outperforms Chemoimmunotherapy in R/R Follicular Lymphoma

Epcoritamab combined with lenalidomide and rituximab showed superior response rates and survival outcomes compared to standard chemoimmunotherapy.

ClinicalJuly 2, 2026

Epizyme's Tazemetostat Shows Promise in Follicular Lymphoma Trial

Stage 1 of the trial assessing Tazemetostat in combination with Lenalidomide and Rituximab has been completed, focusing on safety and tolerability.

CompetitiveJuly 2, 2026

Phase III Trial Compares Rituximab and Mosunetuzumab in Low Tumor Burden Follicular Lymphoma

A phase III trial is underway to compare the effectiveness of rituximab and mosunetuzumab in treating low tumor burden follicular lymphoma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Follicular Lymphoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.